ResearcherYale UniversityNo recent work listed

Yung‐Chi Cheng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109916120. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2014: 1 paper

Papers 1

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Last author DOI 10.1007/s00280-013-2359-7 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Lynne A. Lamb · 1 shared paper, 2014 · strength 0.04
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗
Kristin Kaley · 1 shared paper, 2014 · strength 0.04
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗
Jia Li · 1 shared paper, 2014 · strength 0.04
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗
Muhammad Wasif Saif · 1 shared paper, 2014 · strength 0.04
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.